ONUSIDA celebra el lanzamiento de la prevención del VIH con lenacapavir en Sudáfrica

6 de junio de 2026

Reportado por IA

ONUSIDA ha celebrado el despliegue de lenacapavir en Sudáfrica como un paso histórico en la prevención del VIH. El fármaco inyectable ya está disponible en 360 centros de salud pública de seis provincias. Asimismo, el medicamento ha sido incluido en la lista nacional de medicamentos esenciales.

Sudáfrica puso en marcha el programa de prevención del VIH con lenacapavir el 6 de junio de 2026. ONUSIDA describió este acontecimiento como un logro histórico para el país. El fármaco inyectable está disponible actualmente en 360 centros de salud pública repartidos en seis provincias. Las autoridades han incorporado el medicamento a la lista de medicamentos esenciales de Sudáfrica. ONUSIDA destacó este lanzamiento como una medida importante para ampliar el acceso a opciones eficaces de prevención del VIH.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

5 de junio de 2026 Reportado por IA Imagen generada por IA Verificado por hechos

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

US Pepfar cuts continue to threaten lenacapavir rollout in South Africa

A new NGO report warns that lingering effects of 2025 US Pepfar funding cuts are undermining South Africa's rollout of the six-monthly HIV prevention injection lenacapavir, despite recent US funding restoration efforts and initial shipments. Community infrastructure losses hinder uptake among high-risk groups, even as rollout begins late May.

New HIV pill simplifies treatment for complex cases

1 de junio de 2026 Reportado por IA

A new combination pill containing bictegravir and lenacapavir shows promise for people with HIV who require complex regimens. The phase three ARTISTRY 1 study found it performed as well as existing multi-pill options. Experts note its impact in South Africa will likely remain limited.

Política

Ramaphosa says NHI key to bridging public-private healthcare gap

Asia

Nadda chairs meeting on Ebola preparedness

América

Fiocruz starts full national production of tacrolimus for transplants

Study confirms tenth HIV cure case via stem cell transplant

A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.

1 de junio de 2026 23:11

ONUSIDA celebra el lanzamiento de la prevención del VIH con lenacapavir en Sudáfrica

Artículos relacionados

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

US Pepfar cuts continue to threaten lenacapavir rollout in South Africa

New HIV pill simplifies treatment for complex cases

Ramaphosa says NHI key to bridging public-private healthcare gap

Nadda chairs meeting on Ebola preparedness

Fiocruz starts full national production of tacrolimus for transplants

Study confirms tenth HIV cure case via stem cell transplant

South africa rolls out unprecedented foot and mouth disease vaccination drive

South Africa assesses low risk from new Ebola outbreak

CAR-T cell therapy shows early promise for HIV control

Axel Kicillof announces boost in medication delivery in Buenos Aires

Deputy president highlights TB progress on World TB Day

Este sitio web utiliza cookies